Hims & Hers priced its semaglutide pill at $49 a month, far below Novo’s newly approved oral Wegovy, which starts at $149|Siebuh|CC BY-NC 2.0
Novo Nordisk has warned it will take legal action against Hims & Hers after the telehealth company launched a much cheaper version of Wegovy.
Hims said its compounded semaglutide pill will cost $49 a month, far less than Novo’s $149 starting price.
The Danish pharma giant called the product illegal and warned it could risk patient safety because the Food and Drug Administration does not approve compounded drugs.
The FDA has already warned Hims about marketing its drugs as similar to approved medicines.
Investors reacted quickly to Hims’ announcement, sending Novo shares down 8%.